产前服用阿奇霉素对母亲及其新生儿体内大肠埃希菌和肺炎克雷伯菌的携带和抗生素耐药性的影响:在冈比亚和布基纳法索进行的随机双盲试验的子研究。

IF 8.2 1区 医学 Q1 IMMUNOLOGY
Pauline Getanda, Isatou Jagne, Joel D Bognini, Bully Camara, Bakary Sanyang, Saffiatou Darboe, Ellen Sambou, Momodou Barry, Kady Kassibo, Aminata Cham, Harriet Mendy, Bintou K J Singateh, Ebrahim Ndure, Toussaint Rouamba, Abdoulie Bojang, Christian Bottomley, Benjamin P Howden, Umberto D'Alessandro, Halidou Tinto, Anna Roca
{"title":"产前服用阿奇霉素对母亲及其新生儿体内大肠埃希菌和肺炎克雷伯菌的携带和抗生素耐药性的影响:在冈比亚和布基纳法索进行的随机双盲试验的子研究。","authors":"Pauline Getanda, Isatou Jagne, Joel D Bognini, Bully Camara, Bakary Sanyang, Saffiatou Darboe, Ellen Sambou, Momodou Barry, Kady Kassibo, Aminata Cham, Harriet Mendy, Bintou K J Singateh, Ebrahim Ndure, Toussaint Rouamba, Abdoulie Bojang, Christian Bottomley, Benjamin P Howden, Umberto D'Alessandro, Halidou Tinto, Anna Roca","doi":"10.1093/cid/ciae280","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Limited data exist on the effects of intrapartum azithromycin on the prevalence of carriage and antibiotic resistance of Enterobacterales.</p><p><strong>Methods: </strong>We conducted a randomized trial in The Gambia and Burkina Faso where women received intrapartum azithromycin (2 g) or placebo. We determined the impact of treatment on the prevalence of carriage and antibiotic resistance of Escherichia coli and Klebsiella pneumoniae by analyzing rectal swabs (RS), nasopharyngeal swabs (NPS), breast milk, and rectovaginal swabs (RVS). Bacteria were isolated microbiologically; antibiotic susceptibility was confirmed with an E-test. Prevalence ratios (PRs) with 95% confidence intervals (CIs) were used for comparison between arms.</p><p><strong>Results: </strong>In infants, E. coli carriage in RS was lower in the intervention than in the placebo arm at day 6 (63.0% vs 75.2%; PR, 0.84; 95% CI, .75-.95) and day 28 (52.7% vs 70.4%; 0.75; 0.64-0.87) post-intervention. Prevalence of azithromycin-resistant E. coli was higher in the azithromycin arm at day 6 (13.4% vs 3.6%; 3.75; 1.83-7.69) and day 28 (16.4% vs 9.6%; 1.71; 1.05-2.79). For K. pneumoniae, carriage in RS was higher in the intervention than in the placebo arm at day 6 (49.6% vs 37.2%, 1.33; 1.08-1.64) and day 28 (53.6% vs 32.9%, 1.63; 1.31-2.03). Prevalence of azithromycin-resistant K. pneumoniae was higher in the azithromycin arm at day 28 (7.3% vs 2.1%; 3.49; 1.30-9.37). No differences were observed for other sample types.</p><p><strong>Conclusions: </strong>Intrapartum azithromycin decreased E. coli carriage but increased both K. pneumoniae carriage and azithromycin resistance in both bacteria. These data need to be considered together with efficacy results to balance the potential short- and long-term impact of the intervention. Clinical Trials Registration.  www.clinicaltrials.gov: NCT03199547.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1338-1345"},"PeriodicalIF":8.2000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and Their Newborns: A Substudy of a Randomized, Double-Blind Trial Conducted in The Gambia and Burkina Faso.\",\"authors\":\"Pauline Getanda, Isatou Jagne, Joel D Bognini, Bully Camara, Bakary Sanyang, Saffiatou Darboe, Ellen Sambou, Momodou Barry, Kady Kassibo, Aminata Cham, Harriet Mendy, Bintou K J Singateh, Ebrahim Ndure, Toussaint Rouamba, Abdoulie Bojang, Christian Bottomley, Benjamin P Howden, Umberto D'Alessandro, Halidou Tinto, Anna Roca\",\"doi\":\"10.1093/cid/ciae280\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Limited data exist on the effects of intrapartum azithromycin on the prevalence of carriage and antibiotic resistance of Enterobacterales.</p><p><strong>Methods: </strong>We conducted a randomized trial in The Gambia and Burkina Faso where women received intrapartum azithromycin (2 g) or placebo. We determined the impact of treatment on the prevalence of carriage and antibiotic resistance of Escherichia coli and Klebsiella pneumoniae by analyzing rectal swabs (RS), nasopharyngeal swabs (NPS), breast milk, and rectovaginal swabs (RVS). Bacteria were isolated microbiologically; antibiotic susceptibility was confirmed with an E-test. Prevalence ratios (PRs) with 95% confidence intervals (CIs) were used for comparison between arms.</p><p><strong>Results: </strong>In infants, E. coli carriage in RS was lower in the intervention than in the placebo arm at day 6 (63.0% vs 75.2%; PR, 0.84; 95% CI, .75-.95) and day 28 (52.7% vs 70.4%; 0.75; 0.64-0.87) post-intervention. Prevalence of azithromycin-resistant E. coli was higher in the azithromycin arm at day 6 (13.4% vs 3.6%; 3.75; 1.83-7.69) and day 28 (16.4% vs 9.6%; 1.71; 1.05-2.79). For K. pneumoniae, carriage in RS was higher in the intervention than in the placebo arm at day 6 (49.6% vs 37.2%, 1.33; 1.08-1.64) and day 28 (53.6% vs 32.9%, 1.63; 1.31-2.03). Prevalence of azithromycin-resistant K. pneumoniae was higher in the azithromycin arm at day 28 (7.3% vs 2.1%; 3.49; 1.30-9.37). No differences were observed for other sample types.</p><p><strong>Conclusions: </strong>Intrapartum azithromycin decreased E. coli carriage but increased both K. pneumoniae carriage and azithromycin resistance in both bacteria. These data need to be considered together with efficacy results to balance the potential short- and long-term impact of the intervention. Clinical Trials Registration.  www.clinicaltrials.gov: NCT03199547.</p>\",\"PeriodicalId\":10463,\"journal\":{\"name\":\"Clinical Infectious Diseases\",\"volume\":\" \",\"pages\":\"1338-1345\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/cid/ciae280\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae280","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:关于产前阿奇霉素对肠杆菌携带率和抗生素耐药性影响的数据有限:关于产前服用阿奇霉素对肠杆菌携带率和抗生素耐药性影响的数据有限:我们在冈比亚和布基纳法索进行了一项随机试验,让产妇在产前服用阿奇霉素(2 克)或安慰剂。我们通过分析直肠拭子(RS)、鼻咽拭子(NPS)、母乳和直肠阴道拭子(RVS),确定了治疗对大肠埃希菌和肺炎克雷伯菌携带率和抗生素耐药性的影响。细菌是通过微生物学方法分离出来的;抗生素敏感性是通过 E 试验确认的。采用患病率比(PR)和 95% 置信区间(CI)进行两组间比较:在干预后第 6 天(63.0% 对 75.2%,PR,0.84;CI,0.75-0.95)和第 28 天(52.7% 对 70.4%,0.75;0.64-0.87),干预组婴儿 RS 中的大肠杆菌携带率低于安慰剂组。阿奇霉素组在干预后第6天(13.4% vs. 3.6%,3.75;1.83-7.69)和第28天(16.4% vs. 9.6%,1.71;1.05-2.79)的耐阿奇霉素大肠杆菌感染率较高。就肺炎克氏菌而言,在第 6 天(49.6% 对 37.2%,1.33;1.08-1.64)和第 28 天(53.6% 对 32.9%,1.63;1.31-2.03),干预组 RS 中的携带率高于安慰剂组。阿奇霉素治疗组在第28天时耐阿奇霉素肺炎克氏菌的流行率更高(7.3% vs. 2.1%,3.49;1.30-9.37)。其他样本类型未观察到差异:结论:产前阿奇霉素可减少大肠杆菌携带量,但会增加肺炎双球菌携带量和两种细菌的阿奇霉素耐药性。临床试验注册:www.clinicaltrials.gov:NCT03199547。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and Their Newborns: A Substudy of a Randomized, Double-Blind Trial Conducted in The Gambia and Burkina Faso.

Background: Limited data exist on the effects of intrapartum azithromycin on the prevalence of carriage and antibiotic resistance of Enterobacterales.

Methods: We conducted a randomized trial in The Gambia and Burkina Faso where women received intrapartum azithromycin (2 g) or placebo. We determined the impact of treatment on the prevalence of carriage and antibiotic resistance of Escherichia coli and Klebsiella pneumoniae by analyzing rectal swabs (RS), nasopharyngeal swabs (NPS), breast milk, and rectovaginal swabs (RVS). Bacteria were isolated microbiologically; antibiotic susceptibility was confirmed with an E-test. Prevalence ratios (PRs) with 95% confidence intervals (CIs) were used for comparison between arms.

Results: In infants, E. coli carriage in RS was lower in the intervention than in the placebo arm at day 6 (63.0% vs 75.2%; PR, 0.84; 95% CI, .75-.95) and day 28 (52.7% vs 70.4%; 0.75; 0.64-0.87) post-intervention. Prevalence of azithromycin-resistant E. coli was higher in the azithromycin arm at day 6 (13.4% vs 3.6%; 3.75; 1.83-7.69) and day 28 (16.4% vs 9.6%; 1.71; 1.05-2.79). For K. pneumoniae, carriage in RS was higher in the intervention than in the placebo arm at day 6 (49.6% vs 37.2%, 1.33; 1.08-1.64) and day 28 (53.6% vs 32.9%, 1.63; 1.31-2.03). Prevalence of azithromycin-resistant K. pneumoniae was higher in the azithromycin arm at day 28 (7.3% vs 2.1%; 3.49; 1.30-9.37). No differences were observed for other sample types.

Conclusions: Intrapartum azithromycin decreased E. coli carriage but increased both K. pneumoniae carriage and azithromycin resistance in both bacteria. These data need to be considered together with efficacy results to balance the potential short- and long-term impact of the intervention. Clinical Trials Registration.  www.clinicaltrials.gov: NCT03199547.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信